8
Participants
Start Date
December 8, 2017
Primary Completion Date
November 15, 2019
Study Completion Date
November 15, 2019
Glucocorticoid (prednisone or prednisolone)
≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
Catharina Ziekenhuis, Eindhoven
University of Pittsburgh Medical Center, Pittsburgh
Johns Hopkins University School of Medicine - Baltimore, Baltimore
PMG Research of Wilmington, LLC, Wilmington
Medical University of South Carolina, Charleston
University of Alabama Birmingham, Birmingham
Cleveland Clinic - Taussig Cancer Institute, Cleveland
University of Cincinnati Medical Center, Cincinnati
University of Iowa, Iowa City
Pulmonary and Critical Care Medicine-Washington University School of Medicine, St Louis
MultiCare Institute for Research and Innovation, Tacoma
Erasmus University Medical Center, Rotterdam
Onderzoekscentrum longziekten Zutphen, Zutphen
University College London Hospitals NHS Foundation Trust - University College Hospital, London
Richmond Pharmacology, London
Imperial College London - Hammersmith Hospital Campus, London
University Hospital of South Manchester NHS Foundation Trust -Wythenshawe Hospital - North West Lung, Manchester
Oxford University Hospitals NHS Trust- Churchill Hospital-Oxford Centre for Respiratory Medicine, Oxford
Southmead Hospital, Westbury-on-Trym/ Bristol
The Royal Wolverhampton Hospitals NHS Trust - Newcross Hospital, Wolverhampton
Lead Sponsor
Celgene
INDUSTRY